Johnson & Johnson News

Johnson & Johnson is a large and diverse company, so staying up-to-date with developments, company performance, and their plans for the future is not easy. That's why Wiser created the Johnson & Johnson news digest. It is delivered once a day and contains the key articles from around the web in order to keep you informed. Johnson & Johnson is primarily involved in the health sector. Its interests are spread across 275 different companies in 60 countries. It was founded in 1886 and its headquarters is in New Jersey. Worldwide it employs about 128,000 people and its main consumer brands include Band-Aid, Johnson's baby products and Neutrogena. It also has a medical devices and diagnostics sector, and a pharmaceuticals sector. Challenges exist in the later, particularly regarding the competition from generic versions of some of its drugs. Its research and development pipeline is also watched with interest, as is its movements in terms of expansion - further acquisitions, particularly in the medical devices field, are expected. Make sure you do not miss any Johnson & Johnson news, analysis or information by registering for the free Wiser daily email.

Recent Johnson & Johnson News Coverage
 
Your Weekly Recommendations Wednesday, April 25, 2018
 
Recommended for you
Johnson & Johnson up in pre-market as Q1 results top forecasts
Financial Times
Johnson & Johnson Q1 Preview: Expect Pharmaceuticals To Drive Earnings Growth
Forbes • Contributor, Trefis Team
Another Jury Finds Fault With Johnson & Johnson Over Baby Powder Product
Kaiser Health News
Jury Finds Reckless Indifference of Johnson & Johnson and its Talc Supplier and Awards $80 Million in Punitive Damages for Selling Powder Containing Asbestos
The National Law Review • Clifford Law Offices
IYH: Buy The Holdings, Not The Fund
Seeking Alpha • Dgi Journeyman
BioSci Rounds Report: Strong Data Catapulted Spectrum While Intercept Is Poised For Growth
Seeking Alpha • Biosci Capital Partners
Johnson & Johnson accused of failing to warn patients at higher risk from vaginal mesh
The Guardian • Christopher Knaus
Pfizer: Avoid Pfizer, Buy Johnson & Johnson
Seeking Alpha • William Stamm
Geron: The Better, The Worse And The Uglier
Seeking Alpha • Out
Apax to buy TPG’s healthium medtech for $300 million
The Economic Times of India • E.T. Bureau
 
Recommended for You
Health Care Industry, Johnson & Johnson
Johnson & Johnson up in pre-market as Q1 results top forecasts
Financial Times
Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities
Share
Johnson & Johnson
Johnson & Johnson Q1 Preview: Expect Pharmaceuticals To Drive Earnings Growth
ForbesContributor, Trefis Team
Johnson & Johnson is set to report its Q1 2018 earnings on April 17, and we expect the company to post solid numbers, primarily led by continued growth in oncology drug sales...
Share
Health Reform, Johnson & Johnson
Another Jury Finds Fault With Johnson & Johnson Over Baby Powder Product
Kaiser Health News
This time, Johnson & Johnson was ordered to pay $80 million in damages on charges the company hid that its products were tainted by asbestos. Johnson & Johnson and a talc-mining company were ordered by jurors to pay $80 million in punitive...
Share
Cancer, Johnson & Johnson
Jury Finds Reckless Indifference of Johnson & Johnson and its Talc Supplier and Awards $80 Million in Punitive Damages for Selling Powder Containing Asbestos
The National Law ReviewClifford Law Offices
A New Jersey state jury today (Wednesday, April 11, 2018) slammed Johnson & Johnson and its talc supplier with combined punitive damages of $80 million after finding that the pharmaceutical giant acted with reckless indifference in selling asbestos-containing talcum powder that contributed...
Share
Finance, Health Care Industry
IYH: Buy The Holdings, Not The Fund
Seeking AlphaDgi Journeyman
Summary The iShares U.S. Healthcare ETF offers exposure to companies engaged in the provision of healthcare equipment/services and pharmaceuticals. I'm a fan of many of the top holdings in the ETF, including Johnson & Johnson and UnitedHealth Group. Unfortunately, the 0.42% expense...
Share
Cancer, Health Finance
BioSci Rounds Report: Strong Data Catapulted Spectrum While Intercept Is Poised For Growth
Seeking AlphaBiosci Capital Partners
Summary Intercept insiders accumulated shares aggressively, thus signaling their strong conviction re the robust data that they will present at EASL. Spectrum shares catapulted higher due to upbeat (phase 2) data on poziotinib. FDA approved Johnson & Johnson’s first light adaptive contact...
Share
Johnson & Johnson, Women's Health
Johnson & Johnson accused of failing to warn patients at higher risk from vaginal mesh
The GuardianChristopher Knaus
The pharmaceutical giant Johnson & Johnson allegedly failed to warn women that its vaginal mesh devices posed a particular risk for patients with compromised immune systems, despite it being “well known” before they were first sold in Australia. The federal court is...
Share
Finance, Health Finance
Pfizer: Avoid Pfizer, Buy Johnson & Johnson
Seeking AlphaWilliam Stamm
Summary Pfizer's total return underperformed the Dow average for my 51.0-month test period by 18.18%, which is poor. The company's three-year forward CAGR of 6% (S&P CFRA) is low and will give you slow growth as the United States and foreign economies...
Share
Health Finance, Johnson & Johnson
Geron: The Better, The Worse And The Uglier
Seeking AlphaOut
Summary The Better - Michael West’s improbable search for the fountain of youth morphed into a potential cancer blockbuster that is getting ever closer. The Worse - as Geron thrashes its way to price discovery, the dogs of class action warfare circle....
Share
Hedge Funds, Johnson & Johnson
Apax to buy TPG’s healthium medtech for $300 million
The Economic Times of IndiaE.T. Bureau
British buyout fund Apax Partners is acquiring Healthium Medtech (HMPL) for $300 million (₹1,950 crore) from its existing private equity owners TPG Growth, which holds 73%, homegrown PE firm CX Partners and founding shareholders. This will be London-headquartered Apax’s second healthcare deal...
Share